EternoGen Aesthetics Completes Its Financing Round Securing $5MM to Commercialize Their First in Class Bio-Dermal Restoration Portfolio

Columbia, MO, November 18, 2015 --(PR.com)-- EternoGen Aesthetics, LLC developer and manufacturer of advanced collagen scaffolds, announces the successful completion of its financial round. It has secured $5MM to prepare for the 2016 European commercialization of Rapid Polymerizing Collagen (RPC Pure-Collagen), the first of a rich pipeline of products delivering natural results through Bio-Dermal Restoration in facial aesthetics.

This financing enables RPC Pure-Collagen to complete the European regulatory process. It also provides EternoGen Aesthetics with a strong foundation from which to expand RPC Pure-Collagen production and build a premium brand to create transformative change in the $3B (CAGR 12%) global facial injectable market.

“Completion of this financing round reflects the broad confidence in our unique proposition. The facial injectable market is ripe for innovation and there is a clear need for an option that truly restores the skin’s supporting dermal tissue both structurally and dynamically. Replacing like with like RPC Pure-Collagen will provide natural lasting results particularly in those aesthetically prominent and challenging areas such as lips,” said Anna Tenstam, EternoGen Aesthetics CEO.

At the recent American Society of Dermatological Surgeons (ASDS) conference in Chicago, a panel of leading dermatologists determined RPC Pure-Collagen to be a promising innovation among 6 technologies presented at the Shark Tank session “Entrepreneurs Among us: Take a Risk or Get out of the Water.” 73% of the attending physicians thought RPC Pure-Collagen would enhance procedure outcomes and 65% believed it would improve care for patients.

For more information about EternoGen Aesthetics please visit www.eternogen.com

About RPC Pure-Collagen - RPC Pure-Collagen is a viscous material made of porcine collagen with EDTA and D-Mannitol at a physiological pH provided in a 1 ml Luer-lockTM syringe that can be administered through a fine gauge needle or micro-cannula (30Ga). The viscous composition polymerizes into a fibrous scaffold following injection into dermal or subcutaneous tissue. Following implantation, the RPC Pure-Collagen reacts with local tissue and fibrillogenesis is initiated to convert the collagen solution into a fiber matrix. The EDTA acts as a stabilizer of these collagen fibrils, while the mannitol provides physiologic osmolality. The clinician can manipulate the fiber matrix for a short period (approximately 30 seconds) following implantation to achieve the desired level of correction. The formed matrix provides a scaffold for host fibroblast infiltration and integration with adjacent collagen tissue. The body slowly resorbs the implant.

About EternoGen Aesthetics. EternoGen Aesthetics is a commercial stage Medical Device Company that has developed a transformative pipeline of advanced collagen scaffolds to deliver Bio-Dermal Restoration.

The parent Company EternoGen, LLC was founded in 2009 by an award winning academic research group from the University of Missouri, led by Professor Sheila Grant, a world authority in biomaterials. The management team of EternoGen Aesthetics, LLC is a group of proven industry veterans with strong connections needed for successful commercialization into the aesthetic medicine market.

This news does not constitute an offer of securities for sale in the United States, and no securities may be offered or sold in the United States absent registration under the Securities Act of 1933 and applicable state law, or exemptions thereof.